We provide you with 20 years of free, institutional-grade data for RETA stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of RETA. Explore the full financial landscape of RETA stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2023-08-08 | 1358762 | RETA | 10-Q | Url |
| 2023-05-10 | 1358762 | RETA | 10-Q | Url |
| 2023-02-24 | 1358762 | RETA | 10-K | Url |
| 2022-11-08 | 1358762 | RETA | 10-Q | Url |
| 2022-08-08 | 1358762 | RETA | 10-Q | Url |
| 2022-05-10 | 1358762 | RETA | 10-Q | Url |
| 2022-02-28 | 1358762 | RETA | 10-K | Url |
| 2021-11-08 | 1358762 | RETA | 10-Q | Url |
| 2021-08-09 | 1358762 | RETA | 10-Q | Url |
| 2021-05-06 | 1358762 | RETA | 10-Q | Url |
| 2021-03-01 | 1358762 | RETA | 10-K | Url |
| 2020-11-09 | 1358762 | RETA | 10-Q | Url |
| 2020-08-10 | 1358762 | RETA | 10-Q | Url |
| 2020-05-11 | 1358762 | RETA | 10-Q | Url |
| 2020-02-19 | 1358762 | RETA | 10-K | Url |
| 2019-11-12 | 1358762 | RETA | 10-Q | Url |
| 2019-08-08 | 1358762 | RETA | 10-Q | Url |
| 2019-05-09 | 1358762 | RETA | 10-Q | Url |
| 2019-02-28 | 1358762 | RETA | 10-K | Url |
| 2018-11-07 | 1358762 | RETA | 10-Q | Url |
| 2018-08-08 | 1358762 | RETA | 10-Q | Url |
| 2018-05-08 | 1358762 | RETA | 10-Q | Url |
| 2018-03-02 | 1358762 | RETA | 10-K | Url |
| 2017-11-13 | 1358762 | RETA | 10-Q | Url |
| 2017-08-14 | 1358762 | RETA | 10-Q | Url |
| 2017-05-10 | 1358762 | RETA | 10-Q | Url |
| 2017-03-03 | 1358762 | RETA | 10-K | Url |
| 2016-12-06 | 1358762 | RETA | S-1 | Url |
| 2016-11-14 | 1358762 | RETA | 10-Q | Url |
| 2016-08-11 | 1358762 | RETA | 10-Q | Url |
| 2016-01-04 | 1358762 | RETA | S-1 | Url |
Reata Pharmaceuticals, Inc(NASDAQ:RETA) 
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs,...
Website: http://www.reatapharma.com
Founded: 2002
Full Time Employees: 220
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about RETA stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.